Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

This study tests a combination of radiation therapy and pembrolizumab (an immunotherapy drug) for people with adrenocortical carcinoma (ACC) — a rare cancer of the adrenal glands — that has spread to the liver and other parts of the body. **You may be eligible if...** - You are 15 years of age or older - You have confirmed metastatic adrenocortical carcinoma with liver metastases causing symptoms - You also have cancer spread outside the liver (extrahepatic disease) - Your general health is adequate (ECOG 0–1, or Karnofsky/Lansky ≥50%) - You have measurable disease on imaging **You may NOT be eligible if...** - You are younger than 15 - Your cancer is not confirmed adrenocortical carcinoma - Your cancer has not spread to the liver, or you do not have extrahepatic disease - Your organ function or performance status does not meet minimum standards Talk to your doctor to see if this trial is right for you.